Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 78%
Buy 22%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics Inc. is positioned positively due to its promising pipeline, which includes adeno-associated virus (AAV)-based gene therapies aimed at inherited retinal diseases and innovative treatments for other retinal conditions. Recent data indicates a substantial improvement in visual acuity among treated patients, with significant reported benefits that may encourage accelerated regulatory pathways and enhance the company's growth potential. The strong positive outcomes reported in patient satisfaction and function, combined with a broad array of preclinical assets, suggest a solid foundation for future development and potential financial success.

Bears say

Opus Genetics Inc. faces significant risks that negatively impact its stock outlook, primarily due to the potential for clinical failures in its pipeline of gene therapies, which could lead to delays in regulatory approval or even discontinuation of its programs. The company's target patient population, particularly those with Leber congenital amaurosis (LCA), shows a troubling rate of visual acuity decline, which could complicate treatment outcomes and deter patient enrollment. Furthermore, the presence of multiple serious risks associated with its therapies—such as endophthalmitis, increased intraocular pressure, and retinal abnormalities—exacerbates concerns regarding the safety and efficacy of Opus's offerings, potentially hindering market acceptance and adoption.

Opus Genetics (IRD) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 78% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Opus Genetics (IRD) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.